A case of sustained remission following an acute course of ketamine in treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 72, Issue 3, 2011, Pages 414-415

  Murrough, James W ^a   Perez, Andrew M ^a   Mathew, Sanjay J ^a,b   Charney, Dennis S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; DESVENLAFAXINE; FLUOXETINE; IMIPRAMINE; KETAMINE; LITHIUM SALT; MEMANTINE; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; PAROXETINE; PHENELZINE; RISPERIDONE; SERTRALINE; THYROID HORMONE; TRANYLCYPROMINE; VENLAFAXINE;

ADULT; ANHEDONIA; CASE REPORT; CONCENTRATION LOSS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG RESPONSE; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HUMAN; INSOMNIA; LETTER; MAJOR DEPRESSION; MOOD; PRIORITY JOURNAL; REMISSION; REPEATED DRUG DOSE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDAL IDEATION; THERAPY RESISTANCE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; KETAMINE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 79953057998     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10l06447blu     Document Type: Letter

References (16)

1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. (Pubitemid 30109248)
2. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. (Pubitemid 44188478)
3. Mathew SJ, Murrough JW aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketarnine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71-82.
4. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145.
5. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis Disorders. New York, NY: State Psychiatric Institute, Biometrics Research; 1995.
6. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486. (Pubitemid 26142491)
7. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. (Pubitemid 9136500)
9. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522-526.
10. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. (Pubitemid 37289444)
11. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984-997, 979. (Pubitemid 39524285)
12. Nacher J, Rosell DR, Alonso-Llosa G, et al. NMDA receptor antagonist treatment induces a long-lasting increase in the number of proliferating cells, PSA-NCAM-immunoreactive granule neurons and radial glia in the adult rat dentate gyrus. Eur J Neurosci. 2001;13(3):512-520. (Pubitemid 32158783)
13. Garcia LS, Comim CM, Valvassori SS, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):140-144.
14. Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70(12):1662-1666.
15. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349-352. (Pubitemid 351146651)
16. Machado-Vieira R, Salvadore G, Diazgranados N, et al. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143-150.